Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Hepatitis C: Update Bulletin [May 2016]

Product Code:
596200564
Publication Date:
April 2016
Format:
PDF
Price:
£1,140

This edition presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) treatment market. Topics covered include the potential for Gilead’s sofosbuvir/velpatasvir (SOF/VEL) to become the standard of care in GT2 and GT4 infected patients, following the FDA’s announcement in January 2016 that the regimen had received Priority Review Designation and could be approved in June 2016, and its potential impact on other established therapies such as Harvoni, Technivie/Viekira and Daklinza; how KOLs perceive the role of Gilead’s sofosbuvir/velpatasvir/GS-9857 triple combination therapy, either as a first line agent or salvage therapy; the impact of data from the Phase II SURVEYOR 1 and 2 studies for AbbVie’s ABT-493/ABT-530, and how this data could position ABT-493/ABT-530 as the first pan-genotypic regimen.

Key Business Questions

  • What do KOLs think about the potential for Gilead’s sofosbuvir/velpatasvir (SOF/VEL) to become the standard of care in GT2 and GT4 infected patients, and how could the regimen replace Harvoni as the treatment of choice in GT1 patients?
  • Could Gilead’s sofosbuvir/velpatasvir (SOF/VEL) become the preferred regimen instead of AbbVie’s Technivie/Viekirax (paritaprevir/ombitasvir)?
  • Will Gilead’s sofosbuvir/velpatasvir (SOF/VEL) become the first line regimen in GT2 patients?
  • Do KOLs view Gilead’s triple combination therapy, sofosbuvir/velpatasvir/GS-9857, as a useful addition to the first line treatment of HCV, or will it be used as a salvage therapy?
  • Do KOLs believe that AbbVie’s ABT-493/ABT-530 has the potential to become the first pan-genotypic regimen, based on positive data from the SURVEYOR 1 and 2 studies?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved